At Aplagon we are developing first-in-class therapeutic treatments, APACs, to manage unmet needs in vascular medicine.

APACs target a wide range of vascular intervention related blood vessel occlusions, as well as the prevention of ischemic reperfusion injury. APACs also have potential in other vascular indications.